Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)

NCT04260022 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04260022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04260022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 9, 2020
Completion date
March 31, 2030
Enrollment
242 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b cell precursor type acute leukemia, chronic myeloid leukemia, leukemia, myeloid, chronic, myeloid leukemia, philadelphia positive acute lymphoblastic leukemia